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A 53‐year‐old male known hypertensive presented with lower urinary tract symptoms and a prostate‐specific antigen of 13.6 µg/L. There was no history of recent radiopharmaceutical administration. Abdominal examination was unremarkable, and digital rectal examination revealed an enlarged smooth firm prostate. Systematic transrectal ultrasound‐guided biopsy of the prostate was done, and a diagnosis of prostate adenocarcinoma Gleason score of 3 + 3 = 6 (International Society of Urological Pathology \[ISUP\] 1) was made. Bone scan done as part of metastatic workup showed diffuse liver uptake and found no metastatic bone disease Figure [1](#ccr32351-fig-0001){ref-type="fig"}. Liver function test, hepatitis testing, and liver ultrasound were all normal.
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There has never been a description of liver uptake on bone scan associated with prostate adenocarcinoma in the literature.

Hepatic uptake on a bone scan can reflect recent administration of radiopharmaceuticals or liver disorders such as primary or metastatic disease.[1](#ccr32351-bib-0001){ref-type="ref"} Metastatic disease causes focal faint uptake. Diffuse uptake like in this case is unusual, but can be seen with hepatitis, acute hepatic failure, amyloidosis, intravenous contrast medium administration, etc[2](#ccr32351-bib-0002){ref-type="ref"}

This is the first reported association of prostate adenocarcinoma and diffuse liver uptake on bone scan. This uptake was nonspecific as no liver pathology was detected on further investigations.
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